AMGN vs NXTS vs ZEO Stock Comparison

Amgen, Nexentis Technologies and Zeo Energy Prices as of Oct 29, 2026 Peers: Industry group
AMGN Amgen Inc
$460.73 +8.8% 1M +57.9% 1Y
Market cap
$253.72B
P/E
29.0x
Revenue (TTM)
$38.10B
Div. yield
0.02%
Biotechnology Healthcare
7 wins
ZEO Zeo Energy Corp.
$0.27 -20.6% 1M -83.6% 1Y
Market cap
$8.91M
P/E
–
Revenue (TTM)
$71.82M
Div. yield
–
Solar Installers Industrials
2 wins

Head to Head

9 decided of 12

Amgen leads on 7 of the 12 questions below (Amgen 7, Zeo Energy 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAMGNNXTSZEOLeader
Larger companyMarket capitalisation $253.72B $484.62K $8.91M AMGN
Cheaper on earningsLower P/E, profitable companies only 29.0x 0.0x -0.8x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 21.1x — — –
Faster revenue growthRevenue growth, trailing twelve months +9.1% — +10.2% ZEO
More profitableNet margin, trailing twelve months 23.0% — -15.4% AMGN
Better return on capitalReturn on invested capital 14.3% — -67.1% AMGN
Less leveragedLower net debt / EBITDA 2.7x 1.6x -0.4x ZEO
Higher dividend yieldTrailing dividend yield 0.02% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +57.9% -97.4% -83.6% AMGN
Better 5-year returnAnnualised price return, 5 years +17.4%/yr -85.8%/yr — AMGN
Less volatileAnnualised volatility, 1 year 29.7% 169.0% 118.5% AMGN
Higher overall scoreMean of the five percentile scores vs peers 66/100 32/100 33/100 AMGN

Percentile Scorecard

AMGNNXTSZEO

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAMGNNXTSZEO
Valuation 85 #95 of 624 – 24 #40 of 52
Growth 61 #234 of 601 14 #520 of 601 8 #34 of 37
Profitability 94 #31 of 541 40 #323 of 541 14 #32 of 37
Financial Health 21 #509 of 647 43 #369 of 647 32 #39 of 57
Shareholder Returns 68 #114 of 359 – 89 #4 of 27
Overall 66 32 33
  • AMGN ranked among 671 companies in Pharmaceuticals and Biotechnology
  • NXTS ranked among 671 companies in Pharmaceuticals and Biotechnology
  • ZEO ranked among 57 companies in Construction Services

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAMGNNXTSZEOSPY
1 month +8.8%-55.0%-20.6% +0.7%
3 months +18.9%-59.4%-48.1% +3.7%
6 months +33.1%-86.8%-71.6% +7.1%
Year to date +40.8%-94.6%-75.2% +12.8%
1 year +57.9%-97.4%-83.6% +11.9%
3 years +75.1%-99.9%-97.6% +85.2%
3 years, per year +20.5%-89.7%-71.2% +22.8%
5 years +122.6%-100.0%— +67.6%
5 years, per year +17.4%-85.8%— +10.9%
10 years +217.4%-100.0%— +262.0%
10 years, per year +12.2%-66.2%— +13.7%

Risk

MeasureAMGNNXTSZEOSPY
Volatility, 1Y 29.7%169.0%118.5% 12.7%
Downside volatility, 1Y 28.0%153.5%111.1% 12.6%
Beta vs S&P 500, 1Y 0.452.352.37 1.00
Return / volatility, 1Y 1.95-0.58-0.71 0.94
Max drawdown, 5Y -26.7%-100.0%-98.2% -25.4%
From 52-week high 0.0%-97.4%-84.6% -1.2%
52-week high $460.73$24.15$1.75 $779.14
52-week low $291.77$0.53$0.21 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAMGNNXTSZEO
P/E now vs peer median 28.5xmedian 17.8x 0.0xmedian 17.8x -0.9xmedian 28.1x
P/S now vs peer median 6.5xmedian 9.1x —median 9.1x 0.3xmedian 0.8x
EV/EBITDA now vs peer median 18.2xmedian 15.0x 1.5xmedian 15.0x -2.5xmedian 12.7x
P/FCF now vs peer median 24.5xmedian 21.7x —median 21.7x -3.4xmedian 25.0x
P/B now vs peer median 21.3xmedian 2.2x 0.3xmedian 2.2x 2.3xmedian 2.5x
PEG now vs peer median 10.73median 0.35 0.00median 0.35 0.02median 0.60

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAMGNNXTSZEO
Revenue $38.10B – $71.82M
Gross profit $26.48B – $36.70M
Operating income $11.43B -$5.28M -$11.92M
Net income $8.74B -$14.06M -$11.05M
Free cash flow $10.18B – -$6.29M
R&D $7.63B $532.00K –
EPS (diluted) $16.07 $-17.10 $-0.31
Cash & equivalents $13.99B $7.62M $2.50M
Total debt $57.30B $3.22M $17.94M
Shares (diluted) 544.00M 816.14K 35.84M
Enterprise value $209.12B -$22.16M -$5.37M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAMGNNXTSZEO
P/E 28.5x 0.0x -0.9x
P/FCF 24.5x – -3.4x
P/Operating cash flow 20.0x – -3.9x
P/S 6.5x – 0.3x
P/B 21.3x 0.3x 2.3x
P/Tangible book -28.3x -0.2x 2.3x
EV/EBITDA 18.2x 1.5x -2.5x
EV/EBIT 25.6x 1.5x -2.1x
EV/Revenue 7.7x – 0.3x
EV/FCF 28.7x – -4.0x
EV/Operating cash flow 23.4x – -4.6x
PEG (3Y EPS CAGR) 10.73 0.00 0.02

Growth

14 metrics
MetricAMGNNXTSZEO
Revenue growth (1Y) 9.1% – 10.2%
Revenue CAGR (3Y) 12.7% – –
Gross profit growth (1Y) 17.6% – 1.8%
Gross profit CAGR (3Y) 10.3% – –
Operating income growth (1Y) 39.5% -7.7% 41.7%
Operating income CAGR (3Y) 6.4% 3.0% -144.8%
Net income growth (1Y) 32.1% -48.2% 44.8%
Net income CAGR (3Y) 3.1% -35.8% -47.0%
EPS growth (1Y) 31.4% -567.8% 29.1%
EPS CAGR (3Y) 2.7% -45.2% -39.9%
Operating cash flow growth (1Y) 3.9% – -497.3%
Operating cash flow CAGR (3Y) 4.9% – -44.0%
Free cash flow growth (1Y) -4.1% – -257.2%
Free cash flow CAGR (3Y) 1.7% – -46.5%

Profitability

14 metrics
MetricAMGNNXTSZEO
Gross margin 69.5% – 51.1%
EBITDA margin 42.2% – -14.0%
Operating margin 30.0% – -16.6%
Pretax margin 27.0% – -15.5%
Net margin 23.0% – -15.4%
FCF margin 26.7% – -8.8%
Operating cash flow margin 32.8% – -7.6%
Return on equity 83.8% -157.0% -96.1%
Return on assets 9.3% -71.9% -19.6%
Return on invested capital 14.3% – -67.1%
Return on capital employed 16.7% -31.5% -27.3%
Asset turnover 0.4x – 1.3x
Cash conversion (OCF / net income) 1.4x – 0.5x
Stock comp / revenue 1.3% – 2.7%

Financial Health

11 metrics
MetricAMGNNXTSZEO
Debt / assets 59.9% 2.3% 11.0%
Debt / equity 4.9x 0.2x 0.7x
Net debt / EBITDA 2.7x 1.6x -0.4x
Debt / FCF 5.6x – -1.0x
Liabilities / assets 87.8% 89.8% 83.4%
Equity / assets 12.2% 10.2% 16.6%
Interest coverage 4.3x – -60.1x
Current ratio 1.4x 3.7x 1.6x
Quick ratio 0.9x 3.2x 1.2x
Cash ratio 0.5x 3.2x 0.2x
Altman Z-score 2.37 – -0.41

Shareholder Returns

7 metrics
MetricAMGNNXTSZEO
Dividend yield 2.2% – –
Net buyback yield – – 4.9%
Shareholder yield 2.2% – 4.9%
Payout ratio (earnings) 60.4% – –
Payout ratio (FCF) 51.9% – –
Dividend growth (1Y) 6.3% – –
Dividend CAGR (3Y) 6.7% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAMGNNXTSZEO
Forward P/E 21.1xFY2026 – –
EPS, next fiscal year $21.81FY2026 – –
EPS growth, next FY -0.1%FY2026 – –
EPS growth, the year after +7.2% – –
Revenue, next fiscal year $41.51BFY2026 – –
Revenue growth, next FY +12.9%FY2026 – –
Revenue growth, the year after +2.3% – –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAMGNNXTSZEO
Held by institutions 82.7% – –
Institutions holding 3,161 – –
Change in shares held, QoQ +4.5% – –
Institutions buying 1,452 – –
Institutions selling 1,218 – –
Buyers to sellers 1.19 – –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AMGNNXTSZEO
AMGN 1.00 0.03 0.11
NXTS 0.03 1.00 0.07
ZEO 0.11 0.07 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AMGN, NXTS and ZEO?

Amgen (AMGN) is the largest by market capitalisation: Amgen (AMGN) $253.72B, Nexentis Technologies (NXTS) $484.62K, Zeo Energy (ZEO) $8.91M.

Which company is growing faster?

Zeo Energy (ZEO) grew revenue fastest over the trailing twelve months: Amgen (AMGN) +9.1%, Zeo Energy (ZEO) +10.2%.

Which company is more profitable?

Amgen (AMGN) has the highest net margin (Amgen (AMGN) 23.0%, Zeo Energy (ZEO) -15.4%). On return on invested capital, Amgen (AMGN) leads (Amgen (AMGN) 14.3%, Zeo Energy (ZEO) -67.1%).

Which stock has performed better?

Over the past year Amgen (AMGN) returned the most: Amgen (AMGN) +57.9%, Nexentis Technologies (NXTS) -97.4%, Zeo Energy (ZEO) -83.6%. Over five years, Amgen (AMGN) compounded fastest (Amgen (AMGN) +17.4%/yr, Nexentis Technologies (NXTS) -85.8%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Amgen (AMGN) 0.02%, Nexentis Technologies (NXTS) 0.00%, Zeo Energy (ZEO) 0.00%. Nexentis Technologies (NXTS) and Zeo Energy (ZEO) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Amgen (AMGN) has been the steadiest (Amgen (AMGN) 29.7%, Nexentis Technologies (NXTS) 169.0%, Zeo Energy (ZEO) 118.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, AMGN, NXTS and ZEO?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Amgen (AMGN) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.